McKesson shares receive Neutral rating from Mizuho, driven by oncology growth strategy By Investing.com
On Wednesday, Mizuho (NYSE:) initiated coverage on shares of McKesson Corporation (NYSE:NYSE:) with a Neutral rating, setting a price target of $630. The initiation comes after the company has significantly expanded its business model, particularly with the creation of a substantial oncology platform valued at approximately $35 billion.
According to InvestingPro data, McKesson currently commands a market capitalization of $78.28 billion and maintains a “GREAT” financial health score of 3.15/5, indicating robust operational performance. This new venture is expected to provide McKesson with a long-term growth rate above its peers, with projections of a 12-14% increase in earnings per share (EPS) compound annual growth rate (CAGR) over…
